Segui
David van de Vijver
David van de Vijver
Associate professor, Viroscience, Erasmus Medical Centre, Erasmus University, Rotterdam, The
Email verificata su erasmusmc.nl - Home page
Titolo
Citata da
Citata da
Anno
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...
PloS one 4 (3), e4724, 2009
10582009
Pathogenesis and transmission of swine-origin 2009 A (H1N1) influenza virus in ferrets
VJ Munster, E de Wit, JMA van den Brand, S Herfst, EJA Schrauwen, ...
Science 325 (5939), 481-483, 2009
7352009
An automated genotyping system for analysis of HIV-1 and other microbial sequences
T De Oliveira, K Deforche, S Cassol, M Salminen, D Paraskevis, ...
Bioinformatics 21 (19), 3797-3800, 2005
5602005
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
JJA van Kampen, DAMC van de Vijver, PLA Fraaij, BL Haagmans, ...
Nature communications 12 (1), 267, 2021
5592021
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management
AMJ Wensing, DA Van De Vijver, G Angarano, B sj, C Balotta, E Boeri, ...
The Journal of infectious diseases 192 (6), 958-966, 2005
5512005
Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures
MK Hayden, MJM Bonten, DW Blom, EA Lyle, DAMC van de Vijver, ...
Clinical Infectious Diseases 42 (11), 1552-1560, 2006
5082006
Transmission of drug-resistant HIV-1 is stabilizing in Europe
J Vercauteren, AMJ Wensing, DAMC van de Vijver, J Albert, C Balotta, ...
The Journal of infectious diseases 200 (10), 1503-1508, 2009
3002009
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ...
The Lancet gastroenterology and hepatology, 2017
2702017
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis
SY Rhee, JL Blanco, MR Jordan, J Taylor, P Lemey, V Varghese, ...
PLoS medicine 12 (4), e1001810, 2015
2642015
Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants
JJA van Kampen, DAMC van de Vijver, PLA Fraaij, BL Haagmans, ...
MedRxiv, 2020.06. 08.20125310, 2020
2412020
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical…
JW Eaton, NA Menzies, J Stover, V Cambiano, L Chindelevitch, A Cori, ...
The Lancet Global Health 2 (1), e23-e34, 2014
2292014
Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world
D Frentz, CA Boucher, DA Van De Vijver
AIDs Rev 14 (1), 17-27, 2012
1972012
Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe
LM Hofstra, N Sauvageot, J Albert, I Alexiev, F Garcia, D Struck, ...
Clinical infectious diseases 62 (5), 655-663, 2016
1762016
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
AB Abecasis, AMJ Wensing, D Paraskevis, J Vercauteren, K Theys, ...
Retrovirology 10, 1-13, 2013
1742013
Sustainable HIV treatment in Africa through viral-load-informed differentiated care
A Phillips, A Shroufi, L Vojnov, J Cohn, T Roberts, T Ellman, K Bonner, ...
Nature 528 (7580), S68-S76, 2015
1572015
Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy
A Boerekamps, GE van den Berk, FN Lauw, EM Leyten, ME van Kasteren, ...
Clinical Infectious Diseases 66 (9), 1360-1365, 2018
1542018
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
D Paraskevis, O Pybus, G Magiorkinis, A Hatzakis, AMJ Wensing, ...
Retrovirology 6 (1), 1-11, 2009
1462009
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes
DA van de Vijver, AMJ Wensing, G Angarano, B sj, C Balotta, E Boeri, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 41 (3), 352-360, 2006
1352006
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study
BE Nichols, CAB Boucher, M van der Valk, BJA Rijnders, ...
The Lancet Infectious Diseases 16 (12), 1423-1429, 2016
1192016
Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis
M van Velzen, DAMC van de Vijver, FB van Loenen, ADME Osterhaus, ...
The Journal of infectious diseases 208 (9), 1359-1365, 2013
1092013
Il sistema al momento non pu eseguire l'operazione. Riprova pi tardi.
Articoli 1–20